The Subject Expert Committee (SEC) on COVID-19 on December 10 rejected Serum Institute of India’s (SII) application for Covishield booster dose, reported CNBC-TV18.
Quoting sources, CNBC-TV18 stated: “The SEC did not recommend adding a third dose for the Covishield prescribed vaccination format.”
The SEC met on December 10 to review the applications made by both Serum Institute, which manufactures Oxford-AstraZeneca’s COVID-19 vaccine Covishield in India, and Biological E which makes Corbevax coronavirus vaccine…
